BridgeMD
New treatment option for Severe Aplastic Anemia
Official title Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
ClinicalTrials.gov ID: NCT06254560
What this study is testing
What is Rituximab?
Rituximab is an investigational medicine, being studied as a potential treatment for severe aplastic anemia.
Also referred to as Mabthera.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR). Unlike immune thrombocytopenia (ITP), glucocorticoids and human immunoglobulin (IVIg) are generally ineffective for PTR.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Initial diagnosed SAA with PTR
- Age\>18 years old, regardless of gender
- Initial diagnosed SAA with PTR
- Age\>18 years old, regardless of gender
You likely can't join if
- Allergy to rituximab
- Severe active infection
- Hypogammaglobulinemia
- Pregnant and lactating women
- Heart failure (NYHA classification IV)
- Individuals with epilepsy, dementia, and other mental disorders that require medication treatment who cannot understand or follow the research...
See the full eligibility criteria
- Initial diagnosed SAA with PTR
- Age\>18 years old, regardless of gender
- Initial diagnosed SAA with PTR
- Age\>18 years old, regardless of gender
- Allergy to rituximab
- Severe active infection
- Hypogammaglobulinemia
- Pregnant and lactating women
- Heart failure (NYHA classification IV)
- Individuals with epilepsy, dementia, and other mental disorders that require medication treatment who cannot understand or follow the research protocol
- Chronic infections or other chronic diseases that may be risk to the experiment
- The researchers believe that it is not suitable for participants
The study team makes the final eligibility decision.
Where it's taking place
- Tianjin, Tianjin Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tianjin, Tianjin Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.